Back to EPIC Centres - IARC
RESEARCH INTEREST

NAME/SURNAME

Dr Silvia Franceschi

Qualifications
1973-1979 Medical Diploma (M.D.) 110/110 cum laude
Milan University, Milan, Italy

1979-1983 Post-graduate Diploma in Obstetrics and Gynaecology
Milan University, Milan, Italy

1981-1983 Master of Science in Epidemiology
Oxford University, Oxford, UK

1983-1988 Post-graduate Diploma in Medical Statistics
Pavia University, Pavia, Italy

2005 Habilitation à Diriger des Recherches
University of Lyon 1, Lyon, France


 
Previous employment/research
1979-1980 and 1983-1984 Research Fellow
“Mario Negri” Institute for Pharmacological Research,
Milan, Italy

1981-1983 Research Fellow
Division of Epidemiology, Imperial Cancer Research Fund,
Oxford University, Oxford, UK

1984-2000 Chief of Epidemiology Unit
Aviano Cancer Centre, Aviano, Italy

May 2000-present Group Head and Cluster Coordinator
Infections and Cancer Epidemiology Group, Epidemiology and Biology Cluster, International Agency for Research on Cancer, Lyon, France


 
Academic/Visiting apointments
1980 Visiting Epidemiologist
Slone Epidemiology Unit, Boston University, Boston, USA

1988 Visiting Epidemiologist
Environmental Epidemiology Branch, National Cancer Institute, Bethesda, USA

1993-2000 Professor of Epidemiology and Biostatistics
Post-graduate School of Oncology, Udine University, Udine, Italy

1994-present Advisor
Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy

1996-present Professor of Master in Epidemiology
Italian Epidemiology Association, Torino, Italy



 
Epidemiology and Biology Cluster, IARC - EPIC interests :

Focus on studies on infectious diseases and cancer, most notably human papillomavirus and cervical and oral cancer, HIV and hepatitis C virus and lymphomas, and Helicobacter pylori and stomach cancer. All studies involve broad international collaborations, mainly with Latin America, Asia and Africa. Over the years she has closely collaborated with several research centers in the United States (National Cancer Institute) and Oxford, especially in respect to meta-analyses and pooled analyses (e.g., cancers of the breast, thyroid, and cervix).